IDEAYA Biosciences, in partnership with Servier, announced it has dosed the first patient in its OptimUM-11 global Phase 3 registrational trial. The study is evaluating the combination of darovasertib and crizotinib as an adjuvant therapy for patients with primary uveal melanoma who are at a high risk of metastasis after local therapy. This is a significant development as there are currently no approved adjuvant treatments for this patient population.
This clinical milestone highlights the company's strategy to advance darovasertib across various stages of uveal melanoma treatment. In separate news, Guggenheim analyst Paul Jeng raised the firm's price target on Ideaya Biosciences to $57 from $54 while maintaining a Buy rating, expressing confidence in the potential of another of the company's drug candidates.